Komal Jhaveri, MD, FACP, FASCO Archives | OncUpdates

Komal Jhaveri, MD, FACP, FASCO

Author

Komal Jhaveri, MD, FACP, FASCO

Memorial Sloan Kettering Cancer Center

Latest Videos

Video

T-DXd and Interpreting HER2 Expression in HR+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACP, FASCO | Rahul Gosain, MD, MBA | Rohit Gosain, MD

Video

Ep. 4: Ribociclib and the Evolving Role of Oral SERDs in High-Risk Disease

Laura Huppert, MD | Komal Jhaveri, MD, FACP, FASCO | Heather McArthur, MD | Hope Rugo, MD, FASCO | Rahul Gosain, MD, MBA | Rohit Gosain, MD

Video

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

Laura Huppert, MD | Komal Jhaveri, MD, FACP, FASCO | Heather McArthur, MD | Hope Rugo, MD, FASCO | Rahul Gosain, MD, MBA | Rohit Gosain, MD

Video

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

Laura Huppert, MD | Komal Jhaveri, MD, FACP, FASCO | Heather McArthur, MD | Hope Rugo, MD, FASCO | Rahul Gosain, MD, MBA | Rohit Gosain, MD

Video

Ep. 1: Clinical Insights: Optimizing Ribociclib, Abemaciclib, and Palbociclib Use in Metastatic HR-Positive Breast Cancer

Laura Huppert, MD | Komal Jhaveri, MD, FACP, FASCO | Heather McArthur, MD | Hope Rugo, MD, FASCO | Rahul Gosain, MD, MBA | Rohit Gosain, MD

Video

CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer (Full Video)

Laura Huppert, MD | Komal Jhaveri, MD, FACP, FASCO | Heather McArthur, MD | Hope Rugo, MD, FASCO | Rahul Gosain, MD, MBA | Rohit Gosain, MD

Video

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACP, FASCO | Matthew Kurian, MD

Video

Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACP, FASCO | Matthew Kurian, MD